SELLAS Life Sciences Group specializes in biopharmaceuticals for late stage cancer immunotherapies which cover a significant range of indication for cancer. SELLAS recently appointed Dr. Jonathan Eckard to their team as a Chief Business and Strategy Officer. Dr. Eckard has extensive Wall Street experience inasfar as the biotechnology sector is concerned. His understanding of the healthcare equity markets will go far to assist SELLAS in the development of its galinpepimut-S immunotherapeutic, an agent which has the potential to have an effect on more than 25 different types of cancer cells. Dr. Angelos Stergiou, the Vice Chairman and CEO of SELLAS, applauds the appointment. “We are delighted to have attracted a highly regarded analyst to SELLAS’ executive team. Jon’s knowledge of the biotechnology sector and immunogen-oncology will be pivotal in optimizing the company’s strategic and financial goals.”
SELLAS and founder Dr. Angelos Stergiou’s goal is to give impetus to their differentiated cancer immunotherapy program through building the strength of their management team in the finance, medical and commercial development areas. The acquisition of the expertise such as Dr. Jonathan Eckard will go far to build on the heightened interest in SELLAS’ research after the release of positive clinical data for acute myeloid leukemia, malignant pleural mesothelioma and multiple myeloma. Dr. Eckard has been dubbed the Best up-and-comer and a Rising Star by institutional Investor during his time as a research analyst. “SELLAS’ highly differentiated therapy is positioned optimally in the emerging immunogen-oncology landscape and has the potential to benefit patients across a range of different cancers,” Dr. Eckard said.